CD19 and congenital rubella syndrome: For example, CRS was reported more frequently among patients receiving CD19-directed CAR T cells than among patients treated with B-cell mature antigen (BCMA)-targeting CAR T cells (42%–100% vs. 5%, respectively) [7,8].